anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Constipation symptoms of Parkinson's disease (PD) seriously reduce the quality of life of patients and aggravate the development of the disease, but current treatment options still cannot alleviate the progress of constipation. Electroacupuncture (EA) is a new method for the treatment of constipation, which can effectively treat the symptoms of constipation in PD patients. However, the specific regulatory mechanisms of EA in the treatment of constipation symptoms in PD remain unclear. The aim of this study is to investigate the therapeutic effect of EA on PD constipation rats and its regulatory mechanism. A rotenone (ROT)-induced gastrointestinal motility disorder model was used to simulate the pathological process of constipation in PD. The results showed that EA could effectively promote gastrointestinal peristalsis, reduce α-synuclein accumulation in substantia nigra and colon and colonic injury in rats after ROT administration. Mechanistically, EA activation of the central-cholinergic pathway increases acetylcholine release in the colon. At the same time, EA up-regulated the co-expression of enteric glial cells (EGCs) and α7 nicotinic acetylcholine receptor (α7nAChR). EA increased the expression of choline acetyltransferase (ChAT), neuronal nitric oxide synthase (nNOS), and tyrosine hydroxylase (TH) in the colon of PD rats. Further mechanistic studies showed that EA increased the expression of glial cell-derived neurotrophic factor (GDNF), GFRa1 and p-AKT in colon tissues. The present study confirmed that EA upregulates α7nAChR through a central-cholinergic mechanism to promote GDNF release from EGCs, thereby protecting intestinal neurons and thereby improving gastrointestinal motility.
Upadacitinib 30 mg BID for stage 1. If a patient is a non-responder to Upadacitinib 30 mg, then the study team will stop Upadacitinib and initiate Methylprednisolone IV 30mg twice a day plus Cyclosporine (2 milligram/kilogram (mg/kg) per day aiming for levels 200-400 nanograms per milliliter (ng/mL)) for stage 2.
The present invention provides a preparation method for granules with the functions of spleen invigoration and qi replenishment and spleen-invigorating and qi-replenishing granules prepared by the method. The method comprises the following steps: 1. water is added to required raw medicinal materials which are decocted for two times, and leached decoction in two times is combined, filtered, depressurized and concentrated; 2. ethanol with identical weight with the decoction is added to the decoction to be stirred evenly, placed statically and filtered, filtrate is used for recovering ethanol, and the processes of pressure reduction and concentration are carried out; 3. the spray-drying process is carried out for obtaining dry powder; 4. dextrin is added, granulation is carried out by a drying method, and medical granules are packed. The preparation method for granules with the functions of spleen invigoration and qi replenishment can sufficiently extract the active ingredients of raw medicinal materials. The spleen-invigorating and qi-replenishing granules prepared by the method have the advantages of good stable performance of medicine effect, high raw medicine content, lower dose, no sugar, probability, administration, long shelf life, small volume and convenient storage and transportation. In addition, the medicine ingredients are extracted, which is favorable for patients to digest and absorb the medicine with a fast curative effect. Thereby, the granules are suitable for various patients.
Depression is one of the most common perinatal complications, with 1 in 7 mothers qualifying for a diagnosis of postpartum depression (PPD) and even higher rates for those who identify as Hispanic/Latine, Black or African American, American Indian, or Alaska Native, or by multiple races or ethnicities. This project addresses this major gap in services to prevent PPD, particularly among socioeconomically disadvantaged and minoritized groups. It tests the benefit of a virtual perinatal preventive intervention in English and Spanish to increase access, scalability and address the mental health needs of underserved populations. This project will test the virtual version against the in-person version of a service-ready efficacious preventive intervention in a randomized controlled trial (RCT). This trial will provide a test of a preventive intervention with a strong evidence base that is scalable and can be delivered with fidelity by service providers in settings where obstetric care is received. In this project, pregnant women will be randomized to receive an evidence-based group prevention program (Reach Out, Stay Strong, Essentials for New Moms; ROSE) designed for perinatal populations either a) in person, delivered at the hospital where they are receiving prenatal care or b) virtually, delivered by the same staff via video conferencing, both offered in English and Spanish. Diverse pregnant individuals (N = 900) will be randomized to receive virtual or in-person ROSE. The central outcome, depression, will be assessed via REDCap surveys, prenatally (before the program begins and at the end of gestation) and postpartum (approximately six-weeks, 3, 6, and 12-months after birth). Electronic health records (EHRs) and surveys will be used to examine obstetric, mental health (e.g., standard of care depression screening), and sociodemographic factors linked to health disparities that may impact who benefits most.
A total of 40 chronic hemiplegic subjects were included in the study. The patients were divided into 2 groups by simple randomization method. As the Telerehabilitation Group (TR), Group 1 completed the treatment program, which included upper extremity and lower extremity strengthening exercises, for eight weeks, three days a week for 45-60 minutes, 10 repetitions, with online supervision. Group 2 was planned as a face-to-face training group and the same exercises were performed in the clinical setting, accompanied by a physiotherapist. The evaluations were made before and after the treatment. The Modified Ashworth Scale was used for upper extremity spasticity evaluation. The Wolf Motor Function Test was used to evaluate upper extremity functionality. The Barthel ADL Index was used to evaluate Activities of Daily Living (ADL). The Brunnstrom Staging Survey was used to evaluate the level of motor recovery. The Treatment Satisfaction Inquiry Survey was used to evaluate the satisfaction of the patients with the treatment method. Heart Rate (HR) values and oxygen saturation (SaO2) were measured with Pulse Oximetry to monitor vital signs.
Patients who score less than 6 on the John's Hopkins Highest Level of Mobility (JH-HLM) scale, up to 72 hours after transfer from the ICU to the regular nursing floor will not be enrolled in the ambulatory intervention. They will receive physical therapy standard of care.
Participants who will receive the Implantable Loop Recorder (Reveal-LINQ) inserted just after baseline. This is single intervention and lasts for 3 years after which the patient has the option to have it removed.
A multifunctional gene vector and application thereof in delivering miRNA. The invention belongs to the technical field of biological medicine, and particularly relates to a magnetic nanoparticle multifunctional gene vector modified by fucoidin coated Polyethyleneimine (PEI) and application thereof in miRNA delivery. The nanoparticle inner core is a Polyethyleneimine (PEI) modified Fe  3 O 4  nanoparticle, the surface of the nanoparticle is coated with fucoidin through electrostatic adsorption, and the nanoparticle can be further combined with miRNA through self-assembly for targeted delivery of miRNA. The fucoidin and miRNA are self-assembled layer by layer to the PEI modified magnetic Fe  3 O 4  inner core, the preparation method is simple, the condition is mild, and the operation and the repetition are easy. In addition, the fucose composite nano-carrier can realize tissue targeted delivery by means of the magnetic nano-cores in the carrier, so that systematic targeted treatment of tumors is realized. The nano particles have the characteristics of no immunogenicity, high targeting property and the like, and have good application prospects in functional research based on miRNA, treatment of diseases and clinical application.
High-flow nasal cannula oxygen therapy (HFNC) which meets the patient's ventilation need is a non-invasive ventilation system in which warmed and humidified oxygen is administered to the patient at varying flows with the help of a nasal cannula.This study will be conducted as a randomized controlled study with the participation of 70 nurses working in the pediatric clinics of a public hospital between December 2021 and May 2022, as an experimental group (n=35) and a control group (n=35). In the study, two-stage sampling method will be used to determine the nurses who will take place in the experimental and control groups. After the nurses are stratified according to their professional years, assignment to the experimental and control groups will be made by simple random sampling method. The experimental group will be given a pre-test before the training and a post-test one month after the training. In order to avoid interaction between the two groups, the data of the nurses in the control group will be collected first. The knowledge level of the nurses in the experimental and control groups will be evaluated with the HFNC Information Form.
PURPOSE: To provide the subject new compound having humectant action, cuticle emollient action, etc., and useful as a compounding component for skin cosmetic and hair cosmetic and a production intermediate for agrochemicals, pharmaceuticals, etc. CONSTITUTION: A guanidine derivative of formula I (one of R<1> to R<3> is hydroxyl and the others are H) or its salt, e.g. N-(aminoiminomethyl)-trans-4-hydroxy-L- proline. The compound of formula I can be produced e.g. by reacting a proline compound of formula II with a guanidylating agent (e.g. cyanamide or S- alkylisothiourea). The guanidylation reaction is preferably carried out at 0-200 deg.C for 1-72hr under stirring when cyanamide is used as the guanidylating agent or at 25-200 deg.C for 1-72hr under stirring in the presence of a base such as barium hydroxide or pyridine when the agent is other than cyanamide.
Building Better Caregivers (BBC) was developed for caregivers of patients with Alzheimers' Disease and has been adapted for caregivers of patients with ABI. BBC is a peer-led, problem-solving intervention delivered in 6 group workshop sessions. Key components include problem-solving; making an action plan; managing stress and fatigue, difficult care partner behavior, and difficult thoughts/emotions. Each of the workshops last 60 minutes and usually take place once a week over a 6-8 week span of time.
The invention relates to the field of microorganisms, and particularly relates to bacillus licheniformis and application thereof. The deposited number of the bacillus licheniformis is GDMCC No. 62062. The invention also discloses a product composition which contains the thallus substance and/or metabolite of the bacillus licheniformis. The bacillus licheniformis provided by the invention has killing effect on staphylococcus aureus, escherichia coli, clostridium, salmonella enteritidis and pseudomonas aeruginosa and shows dose dependence. The QX8 purified product inhibited the response of purple bacilli to the signal factor acetylhomoserine lactone, and in another test, the QX8 purified product produced a significant inhibitory effect on purpurin. Compounds produced by bacillus licheniformis QX8 at low concentrations are also able to interfere with cellular responses to signaling factors and inhibit the production of virulence factors, preventing biofilm formation.
Participants randomized to the off-site referral to specialized care and patient navigation group will be linked to primary care for PrEP and, if necessary, HCV treatment by a patient navigator. Given the replicated success of the AntiRetroviral Treatment Access Study (ARTAS) intervention regarding linking HIV-infected individuals to HIV primary care, we adapted ARTAS to facilitate people who inject drugs linkage with PrEP and, if necessary, HCV treatment services. Participants in the off-site care arm will be prescribed PrEP and, if necessary, HCV treatment by their off-site physician. All necessary care will also be provided to participants by their off-site physician. Off-site physicians will be notified that if their patients are placed on a waiting list, unable to afford, or are otherwise unable to immediately access PrEP or HCV treatment, Truvada® and Epclusa® are available to participants of the M2HepPrEP study immediately and free of charge.
Atacicept is a first-in-class, dual anti-B-cell Activation Factor-A Proliferation-Inducing Ligand fusion protein in clinical evaluation for treatment of IgA nephropathy. To compare efficacy and safety of atacicept versus placebo in patients with IgAN, this randomized, double-blind, placebo-controlled phase 2b clinical trial ORIGIN enrolled 116 individuals with biopsy-proven IgA nephropathy. Participants were randomized to atacicept 150, 75, or 25 mg versus placebo once weekly for up to 36 weeks. Primary and key secondary endpoints were changes in urine protein creatinine ratio based on 24-hour urine collection at weeks 24 and 36, respectively, in the combined atacicept 150 mg and 75 mg group versus placebo. The primary endpoint was met at week 24 as the mean urine protein creatinine ratio was reduced from baseline by 31% in the combined atacicept group versus 8% with placebo, resulting in a significant 25% reduction with atacicept versus placebo. At week 36, the key secondary endpoint was met as the mean urine protein creatinine ratio reduced from baseline by 34% in the combined atacicept group versus a 2% increase with placebo, resulting in a significant 35% reduction with atacicept versus placebo. The reduction in proteinuria was accompanied by stabilization in endpoint eGFR with atacicept compared to a decline with placebo at week 36, resulting in significant between-group geometric mean difference of 11%, approximating an absolute difference of 5.7 mL/min/1.73m2. Endpoint galactose deficient IgA1 levels significantly decreased from baseline by 60% versus placebo. The safety profile of atacicept was like placebo. Thus, our results provide evidence to support a pivotal, phase 3 study of atacicept in IgA nephropathy.
PROBLEM TO BE SOLVED: To obtain the subject preparation high in melanogenesis inhibitory effect, stability and safety, and free from unfavorable color and odor. SOLUTION: This skin whitening preparation is obtained by formulating a base preparation for external use with suitably 0.0001-5.0wt.% or so of a (-)-epicatechin-contg. fraction which is afforded by the following process: a polar solvent extract from at least one kind of plant selected from Polygonum cuspidatum Sieb. et Zucc., Polygonum cuspidatum Sieb. et Zucc. var. hachidyoense Ohwi and Polygonum sachalinense Fr. Schm. is concentrated under reduced pressures, the resultant concentrate is dissolved in 30vol.% ethanol again and then subjected to fractionation by resin column chromatography followed by elution with 40vol.% ethanol, and the resultant fraction is further fractionated by silica gel chromatography.
IMPORTANCE: Urinary retention is a common adverse effect after intravesical injection of onabotulinum toxin A (BTX) for overactive bladder (OAB). Reported retention rates range from 1.6% to more than 40%. This variation may be due to varying definitions of retention in the literature.
OBJECTIVE: We aimed to assess the variation in definitions of urinary retention across studies of BTX for the treatment of OAB.
STUDY DESIGN: We performed a systematic review of studies of BTX for OAB by querying MEDLINE and EMBASE according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We included original research studies on adults with overactive bladder treated with BTX and urinary retention reported as an outcome from January 2000 to December 2020.
RESULTS: From 954 results, we identified 53 articles that met inclusion criteria. There were 6 definitions for urinary retention. The majority of studies (60.4%) reported initiating clean intermittent catheterization (CIC) as the metric for retention. Five (9.5%) studies provided no definition despite reporting retention as an adverse event. Twenty studies (37.7%) specified a postvoid residual volume (PVR) threshold for initiating CIC in asymptomatic patients; 19 (35.8%) specified a PVR threshold for CIC in symptomatic patients. The PVR thresholds ranged from 100 to 400 mL. Twenty-three studies (43.4%) did not address asymptomatic elevation of PVR, and 22 (41.5%) did not address how symptomatic patients were managed.
CONCLUSIONS: Urinary retention after BTX injection is inconsistently defined in the literature. Lack of standardization in reporting retention after intravesical BTX prevents accurate assessment of the risk of urinary retention and comparison of outcomes between studies.
Subject in this cohort will be randomized to one of the four following treatment sequences (1 treatment per visit): EGHJ, FEHJ, FGIJ, or FGHK. Where E=Placebo, F= GSK2838232 50mg, G= GSK2838232 100mg, H= GSK2838232 50mg + food, I= Placebo + food, J= GSK2838232 10mg + RTV, K= placebo + RTV.
BACKGROUND: The global rise of chronic diseases, especially cardiovascular disease (CVD), poses a significant public health challenge, being a leading cause of death and disability worldwide. In Iran, the surge in CVD incidence and its risk factors, along with a decrease in the age of onset, has notably increased the reliance on coronary artery bypass grafting (CABG) as a life-saving intervention. Staged hybrid coronary revascularization (HCR), which combines percutaneous coronary intervention with delayed CABG, offers a novel approach for patients with complex coronary artery disease, potentially improving survival and reducing complications. Considering the newness of this treatment method and the limitations of previous studies, we investigated the results of staged HCR in acute ST-elevation myocardial infarction (STEMI) patients in this study.
METHODS: This observational study was performed on consecutive patients with acute STEMI who underwent staged HCR and were referred to Valiasr and Razi hospitals in Birjand from 2015 to 2022. The required information (demographic information, angiography result, and operation side effects) was collected in a checklist. If necessary, the patients were contacted by phone. After collecting the data, they were entered into SPSS version 16 software.
RESULTS: This study was conducted on 33 patients with a mean age of 64.88 ± 9.24 years (69.7% male). The average hospital stay was 11.6 ± 8.9 days (3 to 72 days). The mean ejection fraction and syntax score were 36.5% ± 10.2% and 31.21 ± 6.7, respectively. Following surgery and during hospitalization, arrhythmias were observed, including 33.3% with premature ventricular contractions, 18.1% with atrial fibrillation, and 3.1% with ventricular tachycardia. The average number of pack cells (red blood cells that have been separated for blood transfusion) and creatinine changes before and after hybrid surgery were 640.9 ± 670.9 cc and 0.055 ± 0.07. In the follow-up, 9.09% of patients had late mortality, 6.1% of patients had urinary tract infections during hospitalization, 6.1% of patients had surgical site infections, 3.1% needed dialysis, and none of the studied patients had premature death or need for reintervention.
CONCLUSIONS: The results of our study indicated that staged HCR performed early after an ACS is not associated with significant mortality or complications. Therefore, it is advisable to consider staged HCR as a surgical option in appropriate cases.
The effectiveness of paroxetine extended-release tablets in the treatment of panic disorder (PD) was evaluated in three 10-week, multicenter, flexible-dose studies (Studies 4, 5, and 6) comparing paroxetine extended-release tablets (12.5 to 75 mg daily) to placebo in adult outpatients 19 to 72 years of age who met panic disorder (with or without agoraphobia) criteria according to DSM-IV. These trials were assessed on the basis of their outcomes on 3 variables: (1) the proportions of patients free of full panic attacks at Week 10; (2) change from baseline to Week 10 in the median number of full panic attacks; and (3) change from baseline to Week 10 in the median Clinical Global Impression Severity score. For Studies 4 and 5, paroxetine extended-release tablets was superior to placebo on 2 of these 3 variables. Study 6 failed to consistently demonstrate a statistically significant difference between paroxetine extended-release tablets and placebo on any of these variables.

For all 3 studies, the mean dose of paroxetine extended-release tablets for completers at Week 10 was approximately 50 mg/day. Subgroup analyses did not indicate that there were any differences in treatment outcomes as a function of age or gender.

Long-term maintenance effects of paroxetine in patients with PD were demonstrated in a randomized-withdrawal study using immediate-release paroxetine. Patients who were responders during a 10-week, double-blind trial (followed by a 3-month double-blind maintenance phase) of immediate-release paroxetine were re-randomized to continue immediate-release paroxetine or placebo in a 3-month, double-blind withdrawal phase. Patients randomized to immediate-release paroxetine were statistically significantly less likely to relapse than placebo-treated patients.
An immersive environment based on high-definition 360o video obtained from our simulation centre. Single learners, wearing a VR headset, find themselves in the resuscitation room, at the foot of the bed, leading a trauma team through the assessment and resuscitation of a patient in a virtual choose-your-own-adventure scenario. At several key points in the videos, learners are presented with interactive decision points, and their choices determine how the rest of the video unfolds.
BACKGROUND: Perianal abscess is a common condition among adults. The treatment of choice includes early and efficient drainage. The data regarding risk factors for abscess recurrence, fistula formation, and complications are limited as recent publications mainly focus on patients with inflammatory bowel disease.
OBJECTIVES: To determine risk factors for abscess recurrence and fistula formation with regard to patient and surgical characteristics.
METHODS: A retrospective analysis was performed on patients who presented to the emergency department and were diagnosed with perianal abscess between 2011-2020.
RESULTS: We included 983 consecutive patients; 741 men, average age 43 years. Recurrence was documented in 434 cases. Crohn's disease was reported in 70, of which 50 had recurrent episodes (P < 0.0001); 121 of the 234 patients who smoked had recurrence (P = 0.0078); 8% had short symptomatic period (< 24 hours), which was a predisposing factor for recurrence, P < 0.0001. Patients in the non-recurrent group waited 2.53 hours less for surgical intervention (P < 0.0005(. The average time for recurrent episode was 18.95 ± 33.7 months. Fistula was diagnosed in 16.9% of all cases, while 11.6% were within the recurrent group. Surgical expertise of the physician did not significantly change the recurrence rate.
CONCLUSIONS: Crohn's disease and smoking were the only significant risk factors for recurrence of perianal abscess. Timely intervention and drainage of sepsis should not be delayed. Involvement of more experienced surgeons did not seem to alter the natural history of the disease.